LIPOCINE INC.

(LPCN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about LIPOCINE INC.
05/12Lipocine Says Nonalcoholic Steatohepatitis Treatment Well Tolerated in Open-Label Exten..
MT
05/12Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results
PR
05/12Lipocine Inc. Announces Positive LPCN 1144 Nash Open Label Extension Study Results
CI
05/09LIPOCINE : Q1 Earnings Snapshot
AQ
05/09Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022
PR
05/09Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/25Lipocine Inc. Grants Antares Pharma an Exclusive License to Commercialize TLANDO in the..
CI
04/11LIPOCINE : ANNOUNCES BOARD of DIRECTOR APPOINTMENTS - Form 8-K
PU
04/11LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS
PR
04/11Lipocine Inc. Announces Board Appointments
CI
03/30Lipocine announces its partner received fda approval of tlando
AQ
03/29Lipocine's Partner Company Secures US FDA Approval for Testosterone Replacement Therapy
MT
03/29LIPOCINE : ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO™ - Form 8-K
PU
03/29LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO™
PR
03/29Lipocine Inc. Announces Its Partner Received FDA Approval of TLANDO™
CI
03/15Top Premarket Decliners
MT
03/09Earnings Flash (LPCN) LIPOCINE Posts Q4 Revenue $16.1M
MT
03/09LIPOCINE : Announces Financial Results for the Year Ended December 31, 2021 - Form 8-K
PU
03/09Lipocine Announces Financial Results for the Year Ended December 31, 2021
PR
03/09Lipocine Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/07LIPOCINE : Management Change/Compensation - Form 8-K/A
PU
03/01LIPOCINE : Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH - Form 8-K
PU
03/01Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH
PR
03/01Lipocine Inc. Announces Regulatory Guidance on LPCN 1144 in Non-Cirrhotic Nash
CI
02/04Lipocine announces its partner received fda acceptance of nda resubmission for tlando
AQ
02/03LIPOCINE : ANNOUNCES ITS PARTNER RECEIVED FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO® -..
PU
02/03Lipocine announces its partner received fda acceptance of nda resubmission for tlando®
PR
02/01Clene Names Morgan Brown as Finance Chief
MT
01/28Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO
AQ
01/27LIPOCINE : Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO® - Form..
PU
01/27Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO®
PR
01/27Lipocine Inc. Announces Peer-Reviewed Publication of Positive Phase 3 Study Results for..
CI
01/21Lipocine Chief Financial Officer is Retiring
MT
01/21Lipocine Inc. Announces CFO Changes
CI
01/21Lipocine Inc. Announces Executive Changes
CI
01/05Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference
PR
2021LIPOCINE : ANNOUNCES patient dosed in its Phase 2 Study with LPCN 1148 for management of l..
PU
2021Lipocine Commences Dosing in Phase 2 Study of Liver Cirrhosis Drug
MT
2021Lipocine announces patient dosed in its phase 2 study with lpcn 1148 for management of ..
PR
2021Lipocine Inc. Announces Patient Dosed in its Phase 2 Study with LPCN 1148 for Managemen..
CI
2021LIPOCINE : Q3 Earnings Snapshot
AQ
2021Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2021 - F..
PU
2021Earnings Flash (LPCN) LIPOCINE Reports Q3 Revenue $55,000
MT
2021Lipocine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
2021Lipocine's LPCN 1144 Wins US FDA Fast-Track Designation to Treat Non-Cirrhotic Non-Alco..
MT
2021Lipocine Gets FDA Fast-Track Designation for LPCN 1144 in Non-Cirrhotic NASH
DJ
2021Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-..
PU
2021Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-..
CI
2021Lipocine Announces Multiple Poster Presentations At The American Association For The St..
PU
2021ANTARES PHARMA : Enters into exclusive license agreement with lipocine for tlando in u.s.
AQ
2021LIPOCINE : And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO
AQ
2021LIPOCINE : Signs Deal with Antares Pharma for Commercialization of Tlando in the US; Share..
MT
2021ANTARES PHARMA : Strikes Exclusive License Agreement For Oral Testosterone Replacement The..
MT
2021LIPOCINE : AND ANTARES PHARMA ENTER INTO U.S. Licensing Agreement to Commercialize TLANDO®..
PU
2021LIPOCINE : And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO®
PR
2021TRANSCRIPT : Lipocine Inc. Presents at H.C. Wainwright 5th Annual NASH Investor Conference..
CI
2021LIPOCINE : to Present at The H.C. Wainwright 5th Annual NASH Investor Conference
PR
2021LIPOCINE : Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO
AQ
2021LIPOCINE : Resubmitted New-Drug Application for Tlando Affirmed by FDA
MT
2021LIPOCINE : ANNOUNCES FDA AFFIRMATION of class 1 NDA RESUBMISSION FOR TLANDO® (Form 8-K)
PU
2021LIPOCINE : Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO®
PR
2021Lipocine Inc. Announces FDA Affirmation of Class 1 NDA Resubmission for Tlando®
CI
2021LIPOCINE : to Present at The Cantor Fitzgerald Virtual Global Healthcare Conference
PR
2021LIPOCINE INC.(NASDAQCM : LPCN) added to S&P Global BMI Index
CI
2021LIPOCINE : to Present at The H.C. Wainwright 23rd Annual Global Investment Conference
PR
2021LIPOCINE : HC Wainwright Adjusts Lipocine's Price Target to $3.50 From $2.50, Keeps Buy Ra..
MT
2021LIPOCINE : 1144 Presentation-LiFT Topline 36 Week Results
PU
2021LIPOCINE : Both LPCN 1144 treatment arms met with statistical significance the pre-specifi..
PU
2021LIPOCINE : Says Liver Drug Candidate Met Primary Endpoint in Study
MT
2021LIPOCINE : LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endp..
PR
2021Lipocine Inc. Announces Positive Topline 36-Week Results from Phase 2 Proof of Concept ..
CI
2021LIPOCINE : Q2 Earnings Snapshot
AQ
2021LIPOCINE : Announces Financial Results for the Second Quarter Ended June 30, 2021
PR
2021Lipocine Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
2021AFTER HOURS WATCH LIST SCORECARD : Cidm, lpcn, rfil
MT
1  2  3  4  5Next
Upcoming event on LIPOCINE INC.